DEDIFFERENTIATED CHONDROSARCOMA
Clinical trials for DEDIFFERENTIATED CHONDROSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED CHONDROSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED CHONDROSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for rare, Hard-to-Treat bone cancer
Disease control OngoingThis study tested an oral drug called vismodegib in patients with advanced chondrosarcoma, a rare type of bone cancer that has spread and is difficult to treat. The main goal was to see if the drug could stop the cancer from growing for at least six months. Researchers also track…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Scientists train Patients' own cells to fight advanced cancers
Disease control OngoingThis study is testing a personalized cell therapy called LN-145 for patients with advanced cancers that have stopped responding to standard treatments. Doctors collect a patient's own immune cells from their tumor, grow large numbers of them in a lab, and then infuse them back in…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Immune system boost tested against rare, Tough-to-Treat cancers
Disease control OngoingThis study is testing whether a drug called atezolizumab can help control advanced forms of two rare cancers: chondrosarcoma (bone cancer) and clear cell sarcoma (soft tissue cancer). The drug works by helping the patient's own immune system recognize and attack the cancer cells.…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC